Skip to main content

Advertisement

Log in

Preclinical antitumor activity of the oral platinum analog satraplatin

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Satraplatin is an orally available platinum analog. The purpose of this study was to better characterize satraplatin’s preclinical antitumor efficacy in a variety of sensitive and resistant human tumor cell lines and in a prostate cancer xenograft model and to evaluate the effect of satraplatin on PSA expression and/or secretion in a prostate cancer cell line.

Methods

Satraplatin and its primary metabolite JM-118 were preclinically tested for their cytotoxic activity in a range of cancer cells including: human prostate, those forming the NCI drug screening panel, and those resistant to anti-cancer drugs. Also, the antiproliferative efficacy of satraplatin was tested in vivo in a human prostate cancer model. The effect of satraplatin and JM-118 on PSA transcription was measured by quantitative real time PCR.

Results

Satraplatin and JM-118 inhibited in vitro and in vivo the growth of prostate cancer cells in a dose-dependent fashion. The IC50 cytotoxicity values for satraplatin ranged from 1 to 3 μM for androgen-insensitive cells and was 11 μM for the androgen-sensitive cell line. Interestingly, JM-118 was up to 16-fold more potent than satraplatin. Oral administration of satraplatin to nude mouse PC-3 xenograft models inhibited the growth of these human tumors. Satraplatin had no direct effect on PSA transcription and the observed decrease in secreted PSA correlated with a decrease in cell number. When evaluated in the NCI drug-screening panel, satraplatin was most active in leukemia and small cell lung cancer cell lines.

Both satraplatin and JM-118 were tested on cells resistant to chemotherapeutic agents. Satraplatin and JM-118 were equally active in the cisplatin-resistant A129cp80 ovarian carcinoma cell line, with activity comparable to that observed in the parent line. Neither expression of MDR1, BCRP, MRP1, nor altered tubulin or topoisomerase I were found to mediate resistance to satraplatin or JM-118. Although these resistance mechanisms contribute to drug resistance for a number of chemotherapeutics, they do not appear to play a role in satraplatin resistance.

Conclusions

These results demonstrate that satraplatin and JM-118 have preclinical antitumor activity in human prostate cancer and other tumor types as well, including several cell lines displaying drug resistance to cisplatin, docetaxel and mitoxantrone. In addition, the results suggest that PSA should be further evaluated as a relevant marker of clinical response in patients with prostate cancer treated with satraplatin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Hartmann JT, Lipp HP (2003) Toxicity of platinum compounds. Expert Opin Pharmacother 4:889–901

    Article  PubMed  CAS  Google Scholar 

  2. Petrylak DP, Sartor O, Witjes F, Ferrero J, Berry WR, Koletsky A, Falcon S, Nathan FE, Petrone ME, Sternberg C (2007) A phase III, randomized, double-blind trial of satraplatin and prednisone vs placebo and prednisone for patients with hormone refractory prostate cancer. ASCO Prostate Cancer Proceedings: Abstract 145

  3. Mellish KJ, Barnard CF, Murrer BA, Keller LR (1995) DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines. Int J Cancer 62:717–723

    Article  PubMed  CAS  Google Scholar 

  4. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD, Howell SB (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56:4881–4886

    PubMed  CAS  Google Scholar 

  5. Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR (1993) Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum (IV): an orally active platinum drug. Cancer Res 53:2581–2586

    PubMed  CAS  Google Scholar 

  6. Mellish KJ, Kelland LR, Harrap KR (1993) In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer 68:240–250

    PubMed  CAS  Google Scholar 

  7. Twentyman PR, Wright KA, Mistry P, Kelland LR, Murrer BA (1992) Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res 52:5674–5680

    PubMed  CAS  Google Scholar 

  8. O’Neill CF, Hunakova L, Kelland LR (1999) Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells. Chem Biol Interact 123:11–29

    Article  PubMed  CAS  Google Scholar 

  9. Dixon SC, Knopf KB, Figg WD (2001) The control of prostate-specific antigen expression and gene regulation by pharmacological agents. Pharmacol Rev 53:73–91

    PubMed  CAS  Google Scholar 

  10. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 82:1107–1112

    Article  PubMed  CAS  Google Scholar 

  11. Straub B, Müller M, Krause H, Schrader M, Goessl C, Heicappell R, Miller K (2001) Detection of prostate-specific antigen RNA before and after radical retropubic prostatectomy and transurethral resection of the prostate using “Light-cycler”-based quantitative real-time polymerase chain reaction. Urology 58:815–820

    Article  PubMed  CAS  Google Scholar 

  12. Straub B, Müller M, Krause H, Schrader M, Miller K (2003) Quantitative real-time RT-PCR for detection of circulating prostate-specific antigen mRNA using sequence-specific oligonucleotide hybridization probes in prostate cancer patients. Oncology 65(suppl 1):12–17

    Article  PubMed  CAS  Google Scholar 

  13. Grever MR, Schepartz SA, Chabner BA (1992) The National Cancer Institute: cancer drug discovery and development program. Semin Oncol 19:622–638

    PubMed  CAS  Google Scholar 

  14. NCI/NIH Developmental Therapeutics Program human cell line screen Available at: http://www.dtp.nci.nih.gov

  15. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81:1088–1092

    Article  PubMed  CAS  Google Scholar 

  16. Grieshaber CK, Marsoni S (1986) Relation of preclinical toxicology to findings in early clinical trials. Cancer Treat Rep 70:65–72

    PubMed  CAS  Google Scholar 

  17. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute’s Anticancer Drug Screen panel. Biochem Pharmacol 52:1855–1865

    Article  PubMed  CAS  Google Scholar 

  18. Casazza AM, Fairchild CR (1996) Paclitaxel (Taxol): mechanisms of resistance. Cancer Treat Res 87:149–171

    PubMed  CAS  Google Scholar 

  19. Cabral F, Abraham I, Gottesman MM (1981) Isolation of a taxol-resistant Chinese hamster ovary cell mutant that has an alteration in alpha-tubulin. Proc Natl Acad Sci USA 78:4388–4391

    Article  PubMed  CAS  Google Scholar 

  20. Schibler MJ, Cabral F (1986) Taxol-dependent mutants of Chinese hamster ovary cells with alterations in alpha- and beta-tubulin. J Cell Biol 102:1522–1531

    Article  PubMed  CAS  Google Scholar 

  21. Murphy LD, Herzog CE, Rudick JB, Fojo AT, Bates SE (1990) Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochemistry 29:10351–10356

    Article  PubMed  CAS  Google Scholar 

  22. Minotti AM, Barlow SB, Cabral F (1991) Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem 266:3987–3994

    PubMed  CAS  Google Scholar 

  23. Haber M, Burkhart CA, Regl DL, Madafiglio J, Norris MD, Horwitz SB (1995) Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem 270:31269–31275

    Article  PubMed  CAS  Google Scholar 

  24. Ohta S, Nishio K, Kubota N, Ohmori T, Funayama Y, Ohira T, Nakajima H, Adachi M, Saijo N (1994) Characterization of a taxol-resistant human small-cell lung cancer cell line. Jpn J Cancer Res 85:290–297

    PubMed  CAS  Google Scholar 

  25. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS (1997) Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272:17118–17125

    Article  PubMed  CAS  Google Scholar 

  26. Pizzolato JF, Saltz LB (2003) The camptothecins. Lancet 361:2235–2242

    Article  PubMed  CAS  Google Scholar 

  27. Liu LF, Desai SD, Li TK, Mao Y, Sun M, Sim SP (2000) Mechanism of action of camptothecin. Ann N Y Acad Sci 922:1–10

    Article  PubMed  CAS  Google Scholar 

  28. Kapoor R, Slade DL, Fujimori A, Pommier Y, Harker WG (1995) Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol Res 7:83–95

    PubMed  CAS  Google Scholar 

  29. Glavinas H, Krajcsi P, Cserepes J, Sarkadi B (2004) The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1:27–42

    Article  PubMed  CAS  Google Scholar 

  30. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48–58

    Article  PubMed  CAS  Google Scholar 

  31. Perego P, De Cesare M, De Isabella P, Carenini N, Beggiolin G, Pezzoni G, Palumbo M, Tartaglia L, Pratesi G, Pisano C, Carminati P, Scheffer GL, Zunino F (2001) A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line. Cancer Res 61:6034–6037

    PubMed  CAS  Google Scholar 

  32. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L (2001) In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 48:398–406

    Article  PubMed  CAS  Google Scholar 

  33. Schneider E, Horton JK, Yang CH, Nakagawa M, Cowan KH (1994) Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 54:152–158

    PubMed  CAS  Google Scholar 

  34. Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever M, Bates S, Fojo T (1995) Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest 95:2205–2214

    Article  PubMed  CAS  Google Scholar 

  35. Sternberg CN, Whelan P, Hetherington J, Paluchowska B, Slee PH, Vekemans K, Van Erps P, Theodore C, Koriakine O, Oliver T, Lebwohl D, Debois M, Zurlo A, Collette L, Genitourinary Tract Group of the EORTC (2005) Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68:2–9

    Article  PubMed  CAS  Google Scholar 

  36. Fokkema E, Groen HJ, Bauer J, Uges DR, Weil C, Smith IE (1999) Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J Clin Oncol 17:3822–3827

    PubMed  CAS  Google Scholar 

  37. Sova P, Mistr A, Kroutil A, Zak F, Pouckova P, Zadinova M (2006) Comparative anti-tumor efficacy of two orally administered platinum (IV) drugs in nude mice bearing human tumor xenografts. Anticancer Drugs 17:201–206

    Article  PubMed  CAS  Google Scholar 

  38. Raynaud FI, Boxall FE, Goddard P, Barnard CF, Murrer BA, Kelland LR (1996) Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products. Anticancer Res 16:1857–1862

    PubMed  CAS  Google Scholar 

  39. Loh SY, Mistry P, Kelland LR, Abel G, Harrap KR (1992) Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br J Cancer 66:1109–1115

    PubMed  CAS  Google Scholar 

  40. Kelland LR, Murrer BA, Abel G, Giandomenico CM, Mistry P, Harrap KR (1992) Ammine/amine platinum (IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res 52:822–828

    PubMed  CAS  Google Scholar 

  41. Samimi G, Howell SB (2006) Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters. Cancer Chemother Pharmacol 57: 781–788

    Article  PubMed  CAS  Google Scholar 

  42. Fokkema E, Groen HJ, Helder MN, de Vries EG, Meijer C (2002) JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. Biochem Pharmacol 63:1989–1996

    Article  PubMed  CAS  Google Scholar 

  43. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  PubMed  CAS  Google Scholar 

  44. Dagher R, Li N, Abraham S, Rahman A, Sridhara R, Pazdur R (2004) Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 10:8147–8151

    Article  PubMed  CAS  Google Scholar 

  45. Amorino GP, Mohr PJ, Hercules SK, Pyo H, Choy H (2000) Combined effects of the orally active cisplatin analog, JM216, and radiation in antitumor therapy. Cancer Chemother Pharmacol 46:423–426

    Article  PubMed  CAS  Google Scholar 

  46. Cmelak A, Choy H, Murphy B, DeVore R, Bria B, Day T, Porte K, Johnson D (1999) Phase I study of JM-216 with concurrent radiation in non-small cell lung cancer and squamous cell head and neck cancer. Proc Am Soc Clin Oncol 18 (abstract 1520)

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Katja Wosikowski.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wosikowski, K., Lamphere, L., Unteregger, G. et al. Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemother Pharmacol 60, 589–600 (2007). https://doi.org/10.1007/s00280-007-0502-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-007-0502-z

Keywords

Navigation